Immunotherapy: Changing Patient Outcomes in SCLC

Program Overview

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

Credit Expired
CE Credit Expired

Target Audience

The intended audience for this activity is oncologists, as well as PAs and NPs, who manage patients with small cell lung cancer (SCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the mechanism of action of immune checkpoint inhibitors in small cell lung cancer (SCLC) and how this impacts their efficacy in managing SCLC
  • Utilize an evidence-based approach to managing SCLC with current and emerging immunotherapies
  • Proactively manage potential side effects of immunotherapies
  • Employ a strong patient-provider collaborative approach, including shared decision making, to actively educate and engage patients with SCLC in their care

Activity Faculty


Leora Horn, MD, MSc

Associate Professor, Medicine
Assistant Director, Educator Development Program
Clinical Director, Thoracic Oncology Program
Vanderbilt University Medical Center
Nashville, TN

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources